Sage Journals: Discover world-class research

Abstract

Data and safety monitoring plans are essential for fulfilling assurances that are given to patients enrolling in clinical trials that they will not be exposed to avoidable risks and that any information that may influence their willingness to participate in the clinical trial will be made available to them whether the clinical trial is a phase I, phase II, or phase III effort. In addition to the often explicitly detailed nomination of members of an independent data and safety monitoring board and selection of interim analysis plans for control of type I error and avoidance of conduct of a futile study, data and safety monitoring requires organization with regard to schedules for data collection, active surveillance for adverse events, with special emphasis on serious or unexpected events, and the ability to bring all information within a study and newly accruing information external to the research project together as needed for assessment of patient safety.

Keywords

clinical trials data and safety monitoring plan patient safety monitoring

Get full access to this article

View all access options for this article.

References

National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: ethical principles and guidelines for the protection of human subjects of research. OPPR Reports. 1979.

National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research.

Protection of human subjects.

OPPR Reports. 1994.

Knatterud

, Meinert

, Klimt

Effects of hypoglycemic agents on vascular complications in patient with adult-onset diabetes: IV. A preliminary report on phenformin results.

JAMA 1971; 217: 777–84.

Coronary Drug Project Research Group.

The Coronary Drug Project: initial findings leading to modifications of its research protocol.

JAMA 1970; 214: 1303–13.

National Cancer Institute. Data and safety monitoring example plans—2002. Available at: http://www.cancer.gov/clinicaltrials/conducting/dsm-example-plans.

Ellenberg

, Fleming

T.R.

, DeMets

D.L.

Data monitoring committees in clinical trials: a practical perspective. Chichester (UK): John Wiley; 2002.

Fleming

T.R.

, DeMets

D.L.

Monitoring of clinical trials: issues and recommendations.

Control Clinical Trials 1993; 14: 183–97.

Wittes

Forming your phase III trial's data and safety monitoring board: a perspective on safety.

J Invest Med 2004; 52: 453–8.

National Heart, Lung, and Blood Institute. NHLBI investigator initiated clinical trials guidelines—2003. Available at: http://www.nhlbi.nih.gov/funding/policies/clinical.htm.

10.

Canner

Monitoring long-term clinical trials for beneficial and adverse treatment effects.

Commun Statist Theor Meth 1984; 13: 2369–94.

11.

Thrombolysis in Myocardial Infarction Study Group.

Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial.

N Engl J Med 1989; 320: 618–27.

12.

Paganini-Hill

, Chao

Accuracy of recall of hip fracture, heart attack, and cancer: a comparison of postal survey data and medical records.

Am J Epidemiol 1993; 138: 101–6.

13.

Madow

W.G.

Interview data on chronic conditions compared with information derived from medical records—National Center for Health Statistics report, series 2, number 23. US Department of Health, Education and Welfare; 1967.

14.

Writing Group for the Women's Health Initiative Investigators.

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.

JAMA 2002; 288: 321–33.

15.

Gore

, Sloan

, Price

and the TIMI Investigators. Intracranial hemorrhage, cerebral infarction, and subdural hematoma following acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study (TIMI II pilot and randomized clinical trial).

Circulation 1991; 83: 448–59.

16.

Bovill

, Terrin

M.L.

, Stump

D.C.

for the TIMI Investigators. Hemorrhagic events during treatment with intravenous recombinant tissue-type plasminogen activator, heparin and aspirin in acute myocardial infarction (TIMI) phase II trial.

Ann Intern Med 1991; 115: 256–65.

17.

Canner

Monitoring treatment differences in long-term clinical trials.

Biometrics 1977; 33: 603–15.

18.

Terrin

Efficient use of end points in clinical trials: a clinical perspective.

Stat Med 1990; 9: 155–60, 170–2.

19.

Charache

, Terrin

M.L.

, Moore

and the Investigators of the Multicenter Study of Hydroxyurea. Design of the Multicenter Study of Hydroxyurea.

Control Clin Trials 1995; 16: 432–46.

20.

Fleiss

, Bigger

J.T.

, McDermott

Nonfatal myocardial infarction is, by itself, an inappropriate end point in clinical trials in cardiology.

Circulation 1990; 81: 684–5.

21.

Lubsen

, Kirwan

B.A.

Combined endpoints: can we use them?

Stat Med 2002; 21: 2959–70.

Evaluating and Implementing Data and Safety Monitoring Plans

Abstract

Keywords

Get full access to this article

References